EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutation is one of the most pervasive oncogenic driver mutations in NSCLC, which is found in approximately 15% to 20% of Caucasian patients and 30% to 50% of Asian patients (4–6).